
Azelaic Acid: Treats acne and rosacea bumps; may also help uneven pigmentation. Cysteamine: Can reduce melasma pigmentation in tested topical formulas.


Choose for acne or rosacea bumps, especially when uneven tone is also a concern.
Consider for diagnosed melasma when a suitable topical option is needed.
Can you use both?
They can share a pigment routine. Use cysteamine as directed and azelaic acid at another time of day.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Helps calm inflammation: Acts on pathways involved in acne and rosacea. Affects pigment production: Tyrosinase-related activity may help dark marks.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Affects melanin formation: Cysteamine acts through several pigment pathways. May help melasma: The formula, contact time and tolerance matter.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
Azelaic acid strength should be read together with the product’s indication. Prescription examples include 15% gel for inflammatory rosacea and 20% cream for acne.
15%
20%
Prescription rosacea formulation
Gel formulations are labeled for inflammatory papules and pustules of rosacea. They are not simply a weaker version of a 20% acne cream.
Prescription acne cream
A cream strength used for acne. The cream base and indication differ from the 15% rosacea gel.
Choosing a strength: Choose by the concern and finished product. Cosmetic azelaic acid products are not automatically equivalent to prescription formulations.
Higher strengths: Stinging and irritation can limit use. A larger number does not prove better delivery or better results for a different diagnosis.
Formula matters: Gel, foam and cream vehicles affect delivery and tolerability. Do not compare their percentages as if they were identical formulations.
5% cysteamine cream is the main concentration studied for melasma. Contact time is product-specific; some studied formulas are short-contact treatments rather than overnight creams.
5%
Studied melasma cream
Controlled trials studied this strength. One short-contact trial used a specific cream; follow the current product’s instructions rather than copying a study schedule.
Choosing a strength: Choose a finished topical product with clear instructions for how long to leave it on and when to rinse.
Higher strengths: There is no established benefit from escalating beyond the studied strength. Burning, redness or a persistent rash are reasons to stop and reassess.
Formula matters: Stabilization, the base cream and exposure time affect tolerability. Different cysteamine formulations need not have identical instructions.
Approximate windows, not promises.
First few weeksAssess tolerance and texture; immediate softness can come from the base formula.
First few weeksAssess tolerance first; pigment change is usually slower.
4–8 weeksSubtle changes may appear in some tested products; evidence varies.
4–8 weeksSome studied regimens begin showing pigment improvement.
8–12 weeksCompare photographs in the same lighting and reassess benefit.
8–12 weeksA useful review point for benefit and irritation.
3–6 monthsPhotoaging trials often need several months; expect modest rather than dramatic change.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
6–12 monthsLong-term evidence is limited for many cosmetic actives; continue only if useful.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
Stinging, itching and dryness can occur; reduce use for persistent irritation.
Odour, stinging and irritation may limit use; follow wash-off instructions.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a simple formula and test a small area first. Individual tolerance matters more than an ingredient’s reputation for being gentle.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
It is the usual first choice. Very little is absorbed through the skin, it has a long record, and it is what dermatologists switch people to when retinoids stop. Confirm with the doctor managing your pregnancy.
Data in pregnancy are limited; ask the clinician managing your pregnancy before using.
On the skin. The finished product delivers azelaic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Acts on inflammation, acne-related bacteria and pigment pathways; it is not simply an exfoliating peel.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
On the skin. The finished product delivers cysteamine in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Acts on pigment-related pathways; the cream, contact time and tolerance influence its practical effect.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
Choose for acne or rosacea bumps, especially when uneven tone is also a concern.
Two large vehicle-controlled trials support 15% gel for papulopustular rosacea. Acne has guideline support, but a 10% cosmetic serum should not be assumed equivalent to a studied prescription formula.
Consider for diagnosed melasma when a suitable topical option is needed.
A small placebo-controlled study supports 5% cream over four months. Active-comparator studies are small and do not prove equal efficacy to hydroquinone. The mass shown refers to the free base, not its hydrochloride salt.
Sources